Business
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
WILMINGTON, Del., March 17, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that a
About this update from Prelude Therapeutics Incorporated
[{"type":"text","content":"WILMINGTON, Del., March 17, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that a poster with preclinical data on the Company’s oral KAT6A selective degrader (PRT13722) has been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place from April 17-22. “We look forward to sharing additional preclinical data from our potent and selective first-in-class KAT6A degrader development candidate, PRT13722. We believe that our selective KAT6A degrader, with the potential for improved efficacy and tolerability in combination with other standard of care agents, has the potential to be a promising new therapy for patients with ER+ breast cancer. We expect to file an IND in the middle of this year and enter clinical trials in the second half of 2026,” stated Peggy Scherle, Ph.D., Chief Scientific Officer of Prelude. Details on the poster presentation are as follows: Poster Details:Title: First-in-class potent and selective oral KAT6A degrader development candidate, PRT13722, drives complete tumor regressions as a monotherapy with an improved pre-clinical hematological safety profile.Session Category: Experimental and Molecular TherapeuticsSession Title: Proximity-Induced Drug Discovery 2Session Start: 4/21/2026 2:00 PMSession End: 4/21/2026 5:00 PMLocation: Poster Section 15Poster Board Number: 20Poster Number: 5793 Highly selective KAT6A oral degrader programKAT6 is an emerging and recently validated target in the treatment of ER+ breast cancer. Prelude discovered and is developing first-in-class, highly potent, highly selective and orally bioavailable KAT6A selective degraders. The Company has selected a development candidate and remains on track to file an IND in mid-2026 with phase 1 study initiation planned in the 2nd half of 2026. Prelude believes that selectively degrading KAT6A has the potential for improved efficacy, tolerability and combinability with other agents relative to non-selective inhibitors of KAT6A/B and KAT7. The Company presented initial preclinical data supporting this hypothesis at the AACR Annual Meeting 2025. The presentation can be found at Publications - Prelude Therapeutics. Additionally, on April 18, 2026, Prelude’s Director of Biology and Translational Research, Norman Fultang, Ph...